News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
Netflix Didn't Get Warner, But Chairman Reed Hastings Just Cashed Out $39.8 Million In Stock
Finviz·2026/03/05 18:42
Kohl's Stock Testing a Key Trendline Ahead of Earnings
Finviz·2026/03/05 18:42
Tenaya Therapeutics Stock Jumps After New Alnylam Deal
Finviz·2026/03/05 18:39
EWBC Posts Strong 2025 Revenues: Will the Growth Momentum Continue?
Finviz·2026/03/05 18:39
Strong AI Vision and End-Market Diversification Aids CGNX's Prospects
Finviz·2026/03/05 18:39
Canada: TD Securities on Economic Uncertainty and Trade Developments
101 finance·2026/03/05 18:39
Alt Dominance Signals Possible Third Altseason Breakout
Coinomedia·2026/03/05 18:39
Call for payment service providers to participate in digital euro pilot now open
101 finance·2026/03/05 18:39
Is purchasing Costco (COST) stock a smart move before the upcoming earnings report?
101 finance·2026/03/05 18:33
Is It Time to Rebalance Toward the United States? ETFs in Focus
Finviz·2026/03/05 18:33
Flash
20:36
U.S. federal banking regulators clarify capital treatment rules for tokenized securitiesThe U.S. federal banking regulators jointly issued a FAQ clarifying the capital treatment rules for tokenized securities. Tokenized securities refer to securities whose ownership is represented using distributed ledger technology. The FAQ states that eligible tokenized securities generally receive the same capital treatment under capital rules as their non-tokenized counterparts. Regulators emphasize that capital rules remain technologically neutral, and the technology used for issuing and trading securities usually does not affect capital treatment. Banks holding tokenized securities must follow risk management practices and comply with relevant laws and regulations.
20:02
Tevogen Bio Holdings (Tevogen) has recently taken a key step in its generic drug business strategy, signing a letter of intent to officially begin evaluating the potential acquisition of Apozeal Pharmaceuticals.This move marks Tevogen's accelerated expansion of its generic drug product line to strengthen its market competitiveness in the biopharmaceutical sector. Through this strategic assessment, Tevogen is expected to further integrate industry resources and increase its share in the global generic drug market.
20:01
Tevogen Bio Holdings Inc is currently actively evaluating other transaction opportunities and has strategically focused its priorities on businesses related to the life sciences sector.The company's move aims to further expand its influence in the biotechnology industry and explore potential opportunities for synergistic growth.